
Celgene
LEI 4SIHMF0MOSTTL8CD0X64, SWIFT CELGUSA1XXX
Discover what you can do with Cbonds
Everything you need for fixed income research and monitoring.
- 00:23 Coverage
- 00:40 Bond screener
- 00:54 Parameters
- 01:10 Watchlist, Mobile app
- 01:15 Excel Add-in
Trading Schedule Issuer map
Quotes
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Profile
|
Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
|
General information
-
Organization nameCelgene Corporation
-
Organization statusOperating organization
-
Address86 Morris Avenue, Summit, USA, 07901
-
Site
-
IR Site
News
-
New bond issue: Celgene issued international bonds (US151020AY07) with a 3.45% coupon for USD 1,000.0m maturing in 202701/11/2017
-
New bond issue: Celgene issued international bonds (US151020AX24) with a 2.75% coupon for USD 750.0m maturing in 202301/11/2017
-
New bond issue: Celgene issued international bonds (US151020AW41) with a 4.35% coupon for USD 1,250.0m maturing in 204701/11/2017
-
New bond issue: Celgene issued bonds for USD 500.0m maturing in 2021 with a 2.25% coupon.02/08/2017
-
New bond issue: Celgene sells USD 1,000.0m in 2018 bonds with a 2.125% coupon04/08/2015
IFRS/US GAAP reports
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |
Stocks
General information
-
Organization nameCelgene Corporation
-
Organization statusOperating organization
-
Address86 Morris Avenue, Summit, USA, 07901
-
Site
-
IR Site
Codes
-
LEI4SIHMF0MOSTTL8CD0X64
-
SWIFTCELGUSA1XXX
-
SIC2834 PHARMACEUTICAL PREPARATIONS
-
NACE*** ***
-
NAICS*** ***
-
CIK0000816284









